US2019010476A1PendingUtilityA1
Recombinant Elastase Proteins and Methods of Manufacturing and Use Thereof
Est. expiryDec 4, 2027(~1.4 yrs left)· nominal 20-yr term from priority
C12N 9/64A61P 9/10A61P 9/00A61P 43/00C07K 1/14C12N 15/815C12Y 304/21037C12Y 304/21036C12N 9/6448C12P 21/02A61K 9/19A61K 38/486C07K 2319/50A61K 38/00C07K 2319/00C07K 2319/02C12N 9/50Y02A50/30
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention.
Claims
exact text as granted — not AI-modified1 . A protein comprising (i) an elastase activation sequence comprising an elastase recognition sequence operably linked to (ii) the amino acid sequence of a mature elastase.
2 - 39 . (canceled)
40 . A nucleic acid encoding a protein of claim 1 .
41 - 69 . (canceled)
70 . A vector comprising the nucleic acid molecule of claim 40 .
71 - 72 . (canceled)
73 . A host cell comprising the vector of claim 70 .
74 - 78 . (canceled)
79 . A host cell comprising at least one copy of the nucleic acid molecule of claim 40 integrated into its genome.
80 - 83 . (canceled)
84 . A cell genetically engineered to express the nucleic acid molecule of any one of claim 40 .
85 - 87 . (canceled)
88 . A cell culture supernatant comprising the protein of claim 1 .
89 . A method of producing an elastase protein, comprising culturing the host cell of claim 84 under conditions in which the protein is produced.
90 - 110 . (canceled)
111 . A method of producing an elastase protein, comprising:
(a) culturing the host cell of claim 84 in the presence of a first citrate, succinate or acetate compound; (b) recovering the recombinant proelastase protein from said host cell culture; and (c) optionally, exposing the recombinant proelastase protein to activation conditions to produce a mature elastase protein, thereby producing an elastase protein.
112 - 131 . (canceled)
132 . A method of producing a mature elastase protein, comprising:
(a) lyophilizing the protein of claim 1 to produce a lyophilized proelastase protein; (b) storing the lyophilized proelastase protein; (c) reconstituting the lyophilized proelastase protein; and (d) activating the reconstituted proelastase protein, thereby producing a mature elastase protein.
133 - 150 . (canceled)
151 . A method of producing a mature type I elastase protein comprising subjecting the protein of claim 1 to autoactivation conditions, contacting the protein with a catalytic amount of elastase, or both, thereby producing a mature type I elastase protein.
152 - 189 . (canceled)
190 . A method of producing a mature type I elastase protein comprising:
(a) culturing the host cell of claim 84 under conditions in which the protein is expressed; (b) recovering the expressed protein; (c) purifying the recovered protein; (d) raising the pH of a solution containing the protein or contacting the recovered protein with a catalytic amount of elastase to produce a mature type I elastase protein, thereby producing a mature type I elastase protein.
191 - 224 . (canceled)
225 . A method of producing a formulation of mature elastase protein, comprising:
(a) subjecting the protein of claim 1 to autoactivating conditions to produce mature elastase protein; and (b) formulating the mature elastase protein, thereby producing a formulation of mature elastase protein.
226 - 260 . (canceled)
261 . A method of producing a lyophilized mature type I elastase comprising:
(a) producing a mature type I elastase according to the method of claim 151 ; (b) isolating mature type I elastase; and (c) lyophilizing said isolated mature type I elastase, thereby producing a lyophilized mature type I elastase.
262 - 324 . (canceled)
325 . A liquid formulation comprising a solution of a least 0.1 mg/ml of a protein consisting essentially of SEQ ID NO: 5, 84, or 87 in which the trypsin activity corresponds to less than 2 ng/ml trypsin.
326 - 339 . (canceled)
340 . A formulation made by or obtainable by the method of claim 225 .
341 - 346 . (canceled)
347 . A method of removing one or more incorrectly processed mature elastase proteins from a mixture of correctly and incorrectly processed mature elastase proteins, said method comprising:
(a) subjecting a composition comprising a mixture of correctly and incorrectly processed mature elastase proteins to a pH at which the correctly processed mature enzyme is active; (b) maintaining such pH until such time that one or more incorrectly processed mature elastase proteins are degraded, thereby removing said one or more incorrectly processed mature elastase proteins from a mixture of correctly and incorrectly processed mature elastase proteins.
348 - 373 . (canceled)
374 . A method of producing a pharmaceutical composition comprising a mature type I elastase, said method comprising (i) producing a lyophilized mature type I elastase by the method of claim 261 ; and (ii) reconstituting the lyophilized mature type I elastase in water or a pharmaceutically acceptable carrier, thereby producing a pharmaceutical composition comprising a mature human type I elastase.
375 - 424 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.